Latest:
Role of a Pharmacist in Developing Treatment Pathways and Educating Patients
Ryan Haumschild, PharmD, MS, MBA, reflects on how oncologic pharmacists can help to develop treatment pathways and educate patients on precision medicine.
Authors
Catherine Lee, MD
Latest:
The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab: A Post Hoc Analysis of Agave-201
Dr. Catherine Lee presents a post-hoc analysis of the AGAVE-201 trial, demonstrating that axatilimab achieves consistent overall response rates in patients with chronic graft-versus-host disease regardless of prior lines of therapy, with rapid and durable responses, particularly following ruxolitinib, and a favorable safety profile.
Timothy Cloughesy, MD
Latest:
INDIGO: A Phase 3 Global, Randomized, Double-Blinded Study of Vorasidenib vs Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation
Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.
Michele Reni, MD
Michele Reni, MD, is a Specialist in Medical Oncology at the Department of Medical Oncology at the San Raffaele Research Hospital in Milan.
Latest:
Dr Reni on the Efficacy of Preoperative PAXG in Stage I to III PDAC
Michele Reni, MD, discusses the efficacy of pre-operative PAXG compared with modified FOLFIRINOX in stage I to III PDAC.
Christian Grohe, MD, Evangelical Lung Cancer Hospital
Latest:
The Evolving Treatment Landscape of Small Cell Lung Cancer
Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
David Dingli, MD, PhD
David Dingli, MD, PhD, is a professor of medicine at Mayo Clinic in Rochester, Minnesota.
Latest:
Factors for Selecting Iptacopan in C5 Inhibitor–Naive and –Exposed PNH
Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, detail factors for selecting iptacopan in C5 inhibitor–naive and –exposed PNH.
Tomasz Jankowski, MD, PhD
Tomasz Jankowski, MD, PhD, is the chair of the Department of Pneumology, Oncology and Allergology and an assistant professor in the Faculty of Medicine at the Medical University of Lublin.
Latest:
Dr Jankowski on the Telomere-Targeted Agent THIO With Cemiplimab in Advanced NSCLC
Tomasz Jankowski, MD, PhD, discusses THIO sequenced with cemiplimab for the third-line treatment of patients with ICI-resistant advanced NSCLC.
Sophie Paczesny, MD, PhD
Sophie Paczesny MD, PhD, is a professor in the Department of Microbiology and Immunology and co-leader of the Cancer Immunology Program at the Hollings Cancer Center at the Medical University of South Carolina.
Latest:
Dr Paczesny on ST2 as a Biomarker for Acute GVHD Risk Post-Transplant
Sophie Paczesny MD, PhD, discussed the ability of ST2 to predict the risk of developing aGVHD or death following transplant.
Susan Scott, MD
Susan Scott, MD, is a thoracic medical oncologist, at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; as well as assistant professor of oncology at the Johns Hopkins University School of Medicine
Latest:
Lung Cancer Experts Highlight the Significance and Limitations of ADCs
Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.
Yufei Liu, MD, PhD
Yufei Liu, MD, PhD, is an assistant clinical professor in the Department of Radiation Oncology at City of Hope in Duarte, California.
Latest:
Dr Liu on SBRT and IMRT in Colorectal Cancer
Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.
Melinda L. Telli, MD
Latest:
Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer
Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.
Marina Frimer, MD, FACOG, FACS
Latest:
Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma
Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma